Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03579966 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
A Phase 3 study, sponsored by Catalyst Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 63
- Enrollment target
NCT03579966 is a Phase 3 study that was terminated before completion, run by Catalyst Pharmaceuticals. The registered enrollment target is 63 participants.
The verdict
NCT03579966, a Phase 3 study, was terminated before completion, sponsored by Catalyst Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 63 participants
- Enrollment target
Study Summary
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
Interventions
- DRUG Amifampridine Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2022-08-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03579966
The ClinicalTrials.gov registry entry for NCT03579966 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catalyst Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Amifampridine Phosphate is the first listed.
NCT03579966 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03579966 about?
NCT03579966 is a clinical study titled "Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)". Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.
What is the current status of trial NCT03579966?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 63 participants. The study started on 2018-06-11. Estimated completion is 2022-08-05.
What interventions are being tested in trial NCT03579966?
The interventions under investigation include: Amifampridine Phosphate (DRUG).
Who is sponsoring clinical trial NCT03579966?
This trial is sponsored by Catalyst Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.